{"id":539091,"date":"2021-09-16T08:08:00","date_gmt":"2021-09-16T12:08:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-data-at-idweek-2021\/"},"modified":"2021-09-16T08:08:00","modified_gmt":"2021-09-16T12:08:00","slug":"spero-therapeutics-to-present-data-at-idweek-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-data-at-idweek-2021\/","title":{"rendered":"Spero Therapeutics to Present Data at IDWeek 2021"},"content":{"rendered":"
\n

CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeekTM <\/sup> 2021, taking place virtually from September 29 \u2013 October 3, 2021. Presentations will showcase in vitro<\/em> and in vivo<\/em> studies of Spero\u2019s oral antibiotic investigational candidate tebipenem HBr for the treatment of adults with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) and highlight additional research on the epidemiology and management of cUTI.<\/p>\n

\n Presentations pertaining to tebipenem HBr and the epidemiology and management of cUTI:<\/strong>\n <\/p>\n

\n 1. Title: <\/strong>Tebipenem\u00a0in vitro<\/em>\u00a0activity\u00a0against a\u00a0collection of\u00a0pathogens responsible for urinary tract\u00a0infections\u00a0in the US\u00a0
Presenting Author: <\/strong>Rodrigo Mendes, PhD (Director, JMI Laboratories)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>A1. Novel Agents
Poster Number: <\/strong>1057<\/p>\n

\n 2. Title: <\/strong>
\n In vitro<\/em> activity of tebipenem against clinically significant gram-negative bacteria isolated from patients with cancer
Presenting Author: <\/strong>Bahgat Gerges, PhD (Research Scientist, MD Anderson Cancer Center)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>A1. Novel Agents
Poster Number:<\/strong> 1069<\/p>\n

\n 3. Title:<\/strong> Development of tebipenem MIC antimicrobial susceptibility test for gram-negative bacteria on MicroScan dried gram-negative MIC panels
Presenting Author: <\/strong>Jose Enrique Fernandez (Development Scientist, Beckman Coulter)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>A1. Novel Agents
Poster Number: <\/strong>1079<\/p>\n

\n 4. Title: <\/strong>Pharmacokinetics-pharmacodynamics evaluation of tebipenem pivoxil hydrobromide using the 10-day hollow-fiber\u00a0in vitro<\/em>\u00a0infection model\u00a0
Presenting Author: <\/strong>Brian VanScoy, B.S. (Director, Institute for Clinical Pharmacodynamics)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>A2. PK\/PD Studies
Poster Number: <\/strong>1095<\/p>\n

\n 5. Title: <\/strong>Population pharmacokinetic analyses for tebipenem after the administration of tebipenem pivoxil hydrobromide
Presenting Author: <\/strong>Harish Ganesan, M.S. (Institute for Clinical Pharmacodynamics)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>A2. PK\/PD Studies
Poster Number: <\/strong>1105<\/p>\n

\n 6. Title: <\/strong>Oral tebipenem as step-down therapy following intravenous ertapenem in a 7-day hollow-fiber in vitro<\/em> model
Author: <\/strong>Brian VanScoy, B.S. (Director, Institute for Clinical Pharmacodynamics)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>A2. PK\/PD Studies
Poster Number: <\/strong>1113<\/p>\n

\n 7. Title: <\/strong>Absorption, metabolism, and excretion of [14<\/sup>C]-tebipenem pivoxil hydrobromide (TBP-PI-HBr) following a single oral dose in healthy male subjects
Presenting Author: <\/strong>Vipul Gupta, PhD (Sr. Director, DMPK, Bioanalysis and Clinical Pharmacology, Spero Therapeutics)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>A2. PK\/PD Studies
Poster Number: <\/strong>1120<\/p>\n

\n 8. Title:<\/strong> Bioequivalence of two formulations of oral tebipenem-pivoxil hydrobromide in healthy subjects
Presenting Author: <\/strong>Vipul Gupta, PhD (Sr. Director, DMPK, Bioanalysis and Clinical Pharmacology, Spero Therapeutics)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>A2. PK\/PD Studies
Poster Number:<\/strong> 1121<\/p>\n

\n 9. Title: <\/strong>Effect of aluminum hydroxide\/magnesium hydroxide\/simethicone and omeprazole on the pharmacokinetics of tebipenem pivoxil\u00a0hydrobromide (TBP-PI-HBr) in healthy adult subjects
Presenting Author: <\/strong>Vipul Gupta, PhD (Sr. Director, DMPK, Bioanalysis and Clinical Pharmacology, Spero Therapeutics)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>A2. PK\/PD Studies
Poster Number: <\/strong>1122<\/p>\n

\n 10. Title: <\/strong>
\n In vitro<\/em>\u00a0activity of\u00a0tebipenem and comparators against\u00a0Enterobacterales<\/em>\u00a0collected from patients with bloodstream infections as part of the 2019 global STEWARD surveillance program\u00a0
Presenting Author: <\/strong>Ian Critchley, PhD (Vice President and Head of Clinical Microbiology, Spero Therapeutics)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>A3. Resistance mechanisms
Poster Number: <\/strong>1226<\/p>\n

\n 11. Title:<\/strong> Molecular epidemiology of\u00a0Escherichia coli\u00a0<\/em>causing\u00a0urinary tract infections\u00a0in the United States and\u00a0in vitro<\/em>\u00a0activity of tebipenem, including\u00a0against\u00a0strain lineage and resistant subsets (2018-2020)
Presenting Author: <\/strong>Rodrigo Mendes, PhD (Director, JMI Laboratories)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>A3. Resistance mechanisms
Poster Number: <\/strong>1254<\/p>\n

\n 12. Title: <\/strong>An evaluation of tebipenem in vitro<\/em> activity against a panel of Pseudomonas aeruginosa<\/em> isolates with Efflux, AmpC, and OprD Mutations
Presenting Author: <\/strong>Brian VanScoy, B.S. (Director, Institute for Clinical Pharmacodynamics)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>A3. Resistance mechanisms
Poster Number: <\/strong>1281<\/p>\n

\n 13. Title: <\/strong>
\n In vitro<\/em> analysis of AmpC \u03b2-lactamase induction by tebipenem in Enterobacterales<\/em> and Pseudomonas aeruginosa<\/em>
Presenting Author: <\/strong>Rodrigo Mendes, PhD (Director, JMI Laboratories)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>A6. New drug development (formerly L3)
Poster Number:<\/strong> 1036<\/p>\n

\n 14. Title: <\/strong>
\n In vitro<\/em> activity of tebipenem, an orally available carbapenem agent,\u00a0against a collection of surveillance Gram-positive clinical isolates
Presenting Author: <\/strong>SJ Ryan Arends, PhD (Scientist, JMI Laboratories)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>A6. New drug development (formerly L3)
Poster Number:<\/strong> 1038<\/p>\n

\n 15. Title:<\/strong>
\n In vitro<\/em>\u00a0activity of tebipenem against a recent collection of fastidious organisms recovered from respiratory tract infections\u00a0
Presenting Author: <\/strong>SJ Ryan Arends, PhD (Scientist, JMI Laboratories)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>A6. New drug development (formerly L3)
Poster Number:<\/strong> 1041<\/p>\n

\n 16. Title: <\/strong>
\n In vitro\u00a0<\/em>activity of tebipenem against relevant clinical isolates in the presence of pulmonary surfactant\u00a0
Presenting Author: <\/strong>SJ Ryan Arends, PhD (Scientist, JMI Laboratories)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>A6. New drug development (formerly L3)
Poster Number: <\/strong>1044<\/p>\n

\n 17. Title: <\/strong>Medicare spending on urinary tract infections: a retrospective database analysis
Presenting Author: <\/strong>Eric Hammelman, MBA (Principal, Health Management Associates)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>C11. UTIs
Poster Number: <\/strong>1416<\/p>\n

\n 18. Title: <\/strong>High prevalence of fluoroquinolone-resistant urinary tract infection among US emergency department patients diagnosed with UTI, 2018-2020
Presenting Author: <\/strong>Brett Faine, PharmD, MS (University of Iowa)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>C11. UTIs
Poster Number: <\/strong>1419<\/p>\n

\n 19. Title: <\/strong>Descriptive epidemiology of\u00a0UTI hospitalizations\u00a0in the US,\u00a02018\u00a0
Presenting Author: <\/strong>Marya Zilberberg, MD, MPH (President & CEO, EviMed Research Group)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>C11. UTIs
Poster Number: <\/strong>1420<\/p>\n

\n 20. Title: <\/strong>Empiric antimicrobial prescribing for urinary tract infections in patients discharged from the emergency department
Presenting Author: <\/strong>Megan Rech, PharmD, M.S. (Loyola University Medical Center)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>C11. UTIs
Poster Number: <\/strong>1426<\/p>\n

\n 21. Title:<\/strong> Healthcare resource utilization\u00a0during\u00a0hospitalizations\u00a0with UTI\u00a0in the US,\u00a02018\u00a0
Presenting Author: <\/strong>Marya Zilberberg, MD, MPH (President & CEO, EviMed Research Group)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>C11. UTIs
Poster Number: <\/strong>1427<\/p>\n

\n 22. Title:<\/strong> Descriptive epidemiology of\u00a0emergency department visits with\u00a0cUTI\u00a0in the US,\u00a02012-2018\u00a0
Presenting Author: <\/strong>Marya Zilberberg, MD, MPH (President & CEO, EviMed Research Group)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>C11. UTIs
Poster Number: <\/strong>1430<\/p>\n

\n 23. Title: <\/strong>Epidemiology and 12-month antibiotic use in the outpatient setting among adult patients with complicated urinary tract infections: a retrospective database analysis
Presenting Author: <\/strong>Thomas Lodise, PharmD, PhD (Professor, Pharmacy Practice, Albany College of Pharmacy and Health Sciences)
Date: <\/strong>Wednesday, September 29, 2021
Poster Session: <\/strong>C11. UTIs
Poster Number: <\/strong>1439<\/p>\n

\n About\u00a0Spero<\/strong>\u00a0Therapeutics<\/strong>
Spero Therapeutics, Inc.\u00a0is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.<\/p>\n

Spero\u2019s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In\u00a0September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.<\/p>\n

Spero is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.<\/p>\n

Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.<\/p>\n

For more information, visit\u00a0https:\/\/sperotherapeutics.com<\/em><\/strong><\/a>.<\/p>\n

\n Investor Relations Contact:<\/strong>\u00a0
Ted Jenkins
Vice President, Head of Investor Relations
Tjenkins@sperotherapeutics.com<\/a>
(617) 798-4039<\/p>\n

\n Media Contact:<\/strong>\u00a0
media@sperotherapeutics.com<\/a><\/p>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 \u2013 October 3, 2021. Presentations will showcase in vitro and in vivo studies of Spero\u2019s oral antibiotic investigational candidate tebipenem HBr for the treatment of adults with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) and highlight additional research on the epidemiology and management of cUTI. Presentations pertaining to tebipenem HBr and the epidemiology and management of cUTI: 1. Title: Tebipenem\u00a0in … <\/p>\n

Continue reading “Spero Therapeutics to Present Data at IDWeek 2021”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-539091","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSpero Therapeutics to Present Data at IDWeek 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-data-at-idweek-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spero Therapeutics to Present Data at IDWeek 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 \u2013 October 3, 2021. Presentations will showcase in vitro and in vivo studies of Spero\u2019s oral antibiotic investigational candidate tebipenem HBr for the treatment of adults with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) and highlight additional research on the epidemiology and management of cUTI. Presentations pertaining to tebipenem HBr and the epidemiology and management of cUTI: 1. Title: Tebipenem\u00a0in … Continue reading "Spero Therapeutics to Present Data at IDWeek 2021"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-data-at-idweek-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-16T12:08:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjkwMyM0NDA4MDUxIzIwOTAzNjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-data-at-idweek-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-data-at-idweek-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Spero Therapeutics to Present Data at IDWeek 2021\",\"datePublished\":\"2021-09-16T12:08:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-data-at-idweek-2021\\\/\"},\"wordCount\":1159,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-data-at-idweek-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNjkwMyM0NDA4MDUxIzIwOTAzNjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-data-at-idweek-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-data-at-idweek-2021\\\/\",\"name\":\"Spero Therapeutics to Present Data at IDWeek 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-data-at-idweek-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-data-at-idweek-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNjkwMyM0NDA4MDUxIzIwOTAzNjI=\",\"datePublished\":\"2021-09-16T12:08:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-data-at-idweek-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-data-at-idweek-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-data-at-idweek-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNjkwMyM0NDA4MDUxIzIwOTAzNjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyNjkwMyM0NDA4MDUxIzIwOTAzNjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spero-therapeutics-to-present-data-at-idweek-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spero Therapeutics to Present Data at IDWeek 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Spero Therapeutics to Present Data at IDWeek 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-data-at-idweek-2021\/","og_locale":"en_US","og_type":"article","og_title":"Spero Therapeutics to Present Data at IDWeek 2021 - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc.\u00a0(Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced 23 data presentations at the Infectious Disease Society of America (IDSA) IDWeekTM 2021, taking place virtually from September 29 \u2013 October 3, 2021. Presentations will showcase in vitro and in vivo studies of Spero\u2019s oral antibiotic investigational candidate tebipenem HBr for the treatment of adults with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) and highlight additional research on the epidemiology and management of cUTI. Presentations pertaining to tebipenem HBr and the epidemiology and management of cUTI: 1. Title: Tebipenem\u00a0in … Continue reading \"Spero Therapeutics to Present Data at IDWeek 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-data-at-idweek-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-16T12:08:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjkwMyM0NDA4MDUxIzIwOTAzNjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-data-at-idweek-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-data-at-idweek-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Spero Therapeutics to Present Data at IDWeek 2021","datePublished":"2021-09-16T12:08:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-data-at-idweek-2021\/"},"wordCount":1159,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-data-at-idweek-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjkwMyM0NDA4MDUxIzIwOTAzNjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-data-at-idweek-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-data-at-idweek-2021\/","name":"Spero Therapeutics to Present Data at IDWeek 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-data-at-idweek-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-data-at-idweek-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjkwMyM0NDA4MDUxIzIwOTAzNjI=","datePublished":"2021-09-16T12:08:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-data-at-idweek-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-data-at-idweek-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-data-at-idweek-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjkwMyM0NDA4MDUxIzIwOTAzNjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyNjkwMyM0NDA4MDUxIzIwOTAzNjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spero-therapeutics-to-present-data-at-idweek-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Spero Therapeutics to Present Data at IDWeek 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/539091","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=539091"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/539091\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=539091"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=539091"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=539091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}